Jul 19, 2021
|
Ardelyx Provides Regulatory Update on New Drug Application for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
|
Jun 7, 2021
|
Ardelyx Announces Presentations at ERA-EDTA Virtual Congress 2021
|
May 25, 2021
|
Ardelyx to Present at the Jefferies 2021 Virtual Healthcare Conference
|
May 6, 2021
|
Ardelyx Reports First Quarter 2021 Financial Results and Recent Business Highlights
|
Apr 29, 2021
|
Ardelyx Announces Extension of the PDUFA Review Period for Tenapanor for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis
|
Apr 16, 2021
|
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Apr 14, 2021
|
Ardelyx Collaboration Partner, Kyowa Kirin, Announces Initiation of Phase 3 Clinical Studies of Tenapanor for Hyperphosphatemia in Japan
|
Apr 12, 2021
|
Ardelyx Announces Upcoming Data Presentation at ISN World Congress of Nephrology 2021
|
Mar 30, 2021
|
Ardelyx Announces Poster Presentations, Educational Symposium, and Exhibitor Showcase at National Kidney Foundation 2021 Virtual Spring Clinical Meetings
|
Mar 15, 2021
|
Ardelyx Appoints Muna Bhanji, R.Ph, to its Board of Directors
|